Jefferies Global Healthcare Conference
Logotype for Guardant Health Inc

Guardant Health (GH) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Guardant Health Inc

Jefferies Global Healthcare Conference summary

18 Nov, 2026

Portfolio momentum and Guardant360

  • Guardant360 volume growth remained nearly 30%; Guardant Reveal grew over 100% YoY, while Shield volumes reached roughly 3x.

  • Next year, a complete launch of FDA-approved Guardant360 Liquid CDx is expected to support further volume growth.

  • Eleven new Smart Apps launched, including blood-based PD-L1 characterization and immune checkpoint inhibitor prediction; additional launches are planned next year.

  • The Smart Apps platform draws on real-world evidence from hundreds of thousands of patients with EMR, claims and outcomes data.

  • SERENA-6-related breast cancer testing is starting to lift volumes; physician education continues with AstraZeneca and advocacy groups.

Therapy monitoring and tissue testing

  • Nearly 1 million late-stage patients may require therapy selection and repeated response monitoring, representing millions of potential U.S. tests.

  • Guardant360 genomic profiling may be repeated at each cancer progression as tumors evolve and treatment options change.

  • Guardant360 Tissue combines genomics, transcriptomics and methylation, uses less tissue and has low QNS rates; Q2-to-Q3 growth was its largest sequential increase to date.

  • FDA approval for Guardant360 Tissue is targeted for next year; management expects approval and the full Liquid CDx launch to support growth and higher tissue-liquid attachment.

  • Longer term, management expects therapy response monitoring and MRD markets to converge as metastatic drugs move earlier in treatment.

MRD and biopharma data

  • Guardant Reveal and Reveal Ultra are positioned for distinct MRD needs: tissue-free speed and broader tumor detection, and tumor-informed ultra-sensitive testing.

  • Thousands of samples are being run to support clinical-validity studies across major tumor types; data will be presented as it becomes ready.

  • Biopharma work is a fast-growing segment, spanning trial testing, patient monitoring and early treatment-response readouts at 4, 8 and 12 weeks.

  • Data and methylation capabilities may help pharma segment patients for drugs without traditional genomic biomarkers; management sees growth opportunities in coming years.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Guardant Health